Form 4: Penumbra President's Equity Grant and Tax Withholding

Penumbra Inc.'s President, Shruthi Narayan, reported recent restricted stock unit grants and shares withheld for tax obligations.

Summary

• Shruthi Narayan, President of Penumbra Inc., received two grants of Restricted Stock Units (RSUs) under the Issuer's Amended and Restated 2014 Equity Incentive Plan.
• On February 13, 2026, 2,630 RSUs were granted, with 1/4 vesting equally on February 15, 2026, February 15, 2027, February 15, 2028, and February 15, 2029, subject to continued service.
• On February 17, 2026, an additional 2,630 RSUs were granted, with 1/4 vesting equally on an annual basis, beginning on February 15, 2027, subject to continued service.
• A total of 705 shares were disposed of on February 15, 2026, to satisfy tax withholding obligations related to RSU vesting, at a price of $339.3 per share.
• Following these transactions, Shruthi Narayan's direct beneficial ownership of Common Stock increased to 30,872 shares.
• All unvested RSUs will fully vest upon the 'Closing' of an Agreement and Plan of Merger, dated January 14, 2026, among Penumbra Inc., Boston Scientific Corporation, and Pinehurst Merger Sub, Inc., subject to continued service through such date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting routine executive compensation and the explicit mention of a potential strategic merger, which typically signals growth or value realization for the company.

Positives

• The granting of 5,260 Restricted Stock Units (RSUs) to the President aligns executive incentives with the long-term performance and growth of Penumbra Inc.
• The potential for accelerated vesting of RSUs upon the 'Closing' of the merger with Boston Scientific Corporation provides a clear incentive for successful completion of the transaction.

Negatives

• The disposition of 705 shares for tax withholding purposes reduces the direct beneficial ownership of the reporting person, though this is a standard practice for equity compensation.

Risks

• RSU vesting is subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates.
• The accelerated vesting of unvested RSUs is contingent upon the 'Closing' of the merger agreement with Boston Scientific Corporation and Pinehurst Merger Sub, Inc., implying a risk if the merger does not close.

Future Outlook

The filing indicates a significant corporate event with the potential 'Closing' of a merger agreement between Penumbra Inc. and Boston Scientific Corporation, which would accelerate the vesting of unvested Restricted Stock Units for the reporting person.

Management Comments

• The equity grants to President Shruthi Narayan demonstrate the company's commitment to aligning executive incentives with long-term performance and shareholder value.

Industry Context

StockSavvy.ai notes that equity grants are a standard practice to incentivize executives and align their interests with shareholders. The explicit mention of a potential merger with Boston Scientific Corporation suggests a strategic move within the medical device industry, potentially indicating consolidation, market expansion, or a strategic partnership, which are common trends for growth and competitive positioning.

Comparison to Industry Standards

• Equity compensation, particularly Restricted Stock Units (RSUs) with multi-year vesting schedules, is a common practice across industries, including medical devices, to retain and incentivize key executives.
• The provision for accelerated vesting upon a change of control (such as a merger) is also a standard clause in many executive equity plans, designed to protect executive compensation interests during significant corporate transactions.
• The filing does not provide specific details on comparable companies, projects, or results to allow for a detailed assessment against industry benchmarks regarding the size or terms of the RSU grants.

Stakeholder Impact

• Shareholders: The RSU grants align executive interests with long-term shareholder value. The potential merger with Boston Scientific Corporation could significantly impact share value and strategic direction.
• Employees: While this filing specifically relates to one executive, the mentioned merger could have broader implications for the company's workforce, including potential integration or restructuring.

Next Steps

• Continued service by Shruthi Narayan to meet RSU vesting conditions.
• Potential 'Closing' of the merger with Boston Scientific Corporation, which would trigger accelerated RSU vesting.

Key Dates

Recommendation

The filing primarily details routine executive equity compensation and tax-related share disposals. However, the explicit mention of an 'Agreement and Plan of Merger' with Boston Scientific Corporation is a significant development. Without further details on the merger terms (e.g., acquisition price, synergies, regulatory hurdles), a definitive 'buy' or 'sell' recommendation is premature. The RSU grants align management's interests, but the overarching merger news warrants a 'hold' until more information becomes available.

Keywords

Penumbra, PEN, Shruthi Narayan, Form 4, Restricted Stock Units, RSU, Equity Grant, Insider Transaction, Tax Withholding, Boston Scientific, Merger